information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: July 8, 1996.

Bob Sargis,
Acting Director, Office of Information Services.

[FR Doc. 96-17762 Filed 7-11-96; 8:45 am]
BILLING CODE 4184-01-M

---

Food and Drug Administration Advisory Committee; Renewal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) announces the renewal of the Transmissible Spongiform Encephalopathies Advisory Committee (formerly Ad Hoc Advisory Committee on Creutzfeldt-Jakob Disease) by the Commissioner of Food and Drugs. The Commissioner has determined that it is in the public interest to renew the charter of the Committee for an additional 2 years. At the time of charter renewal, the Committee's name and function were changed to more accurately describe the Committee and because the Committee is no longer serving in an ad hoc capacity. Elsewhere in this issue of the Federal Register the agency is issuing a final rule that announces the addition of the Transmissible Spongiform Encephalopathies Advisory Committee to the agency's list of standing advisory committees (21 CFR 14.100). This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92-463 (5 U.S.C. app.2)).

DATES: Authority for this committee will expire on June 9, 1998, unless the Commissioner formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Donna M. Combs, Committee Management Office (HFA-306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-2765.

Dated: July 5, 1996.

Michael A. Friedman,
Deputy Commissioner for Operations.

[FR Doc. 96-17688 Filed 7-11-96; 8:45 am]
BILLING CODE 4160-01-F